# Phase I Dose Escalating Study of TKI258

> **NCT01471548** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** TKI258

## Key facts

- **NCT ID:** NCT01471548
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01471548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01471548, "Phase I Dose Escalating Study of TKI258". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01471548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*